{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:13:49Z","timestamp":1791180829823,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2746,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Ascenta Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1093\/annonc\/mdr555","type":"journal-article","created":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T20:16:38Z","timestamp":1322079398000},"page":"1803-1808","source":"Crossref","is-referenced-by-count":122,"title":["Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"G.","family":"Sonpavde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Matveev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Caton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.R.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Karlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Holmlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr555_bb0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr555_bb0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr555_bb0020","first-page":"6940","article-title":"Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer","volume":"52","author":"McDonnell","year":"1992","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr555_bb0025","first-page":"1567","article-title":"Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers","volume":"148","author":"Krajewska","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdr555_bb0030","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/S0022-5347(05)68095-0","article-title":"p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy","volume":"162","author":"Stackhouse","year":"1999","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdr555_bb0035","first-page":"6052","article-title":"Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity","volume":"60","author":"Lebedeva","year":"2000","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr555_bb0040","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1158\/0008-5472.CAN-05-3691","article-title":"Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2","volume":"66","author":"Zeitlin","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr555_bb0045","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1535-7163.MCT-08-0333","article-title":"Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa","volume":"7","author":"Meng","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdr555_bb0050","first-page":"91","article-title":"The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway","volume":"24","author":"Jiang","year":"2004","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdr555_bb0055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/cdd.2010.74","article-title":"A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum","volume":"18","author":"Lian","year":"2011","journal-title":"Cell Death Differ"},{"key":"10.1093\/annonc\/mdr555_bb0060","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","article-title":"Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma","volume":"111","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr555_bb0065","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-08-2985","article-title":"An open-label, multicenter, phase I\/II study of single-agent AT-101 in men with castrate-resistant prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr555_bb0070","doi-asserted-by":"crossref","unstructured":"MSalehHPitotJHolmlundExtended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancersJ Clin Oncol 2007; 25 (18S): 3583. ASCO Annual Meeting Proceedings Part I Abstracts","DOI":"10.1200\/jco.2007.25.18_suppl.3583"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr555_bb0075","first-page":"15s","article-title":"An open-label, multicenter, phase I\/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC)","volume":"27","author":"MacVicar","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr555_bb0080","first-page":"15s","article-title":"Preliminary report of an open-label, multicenter, phase I\/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer","volume":"27","author":"Poiesz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr555_bb0085","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdr555_bb0090","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejca.2009.11.007","article-title":"The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival","volume":"46","author":"Armstrong","year":"2010","journal-title":"Eur J Cancer"},{"issue":"9747","key":"10.1093\/annonc\/mdr555_bb0095","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"37","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"10.1093\/annonc\/mdr555_bb0100","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr555_bb0105","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djj129","article-title":"Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16","volume":"98","author":"Petrylak","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1093\/annonc\/mdr555_bb0110","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdr555_bb0115","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/cdd.2009.48","article-title":"Different forms of cell death induced by putative BCL2 inhibitors","volume":"16","author":"Vogler","year":"2009","journal-title":"Cell Death Differ"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr555_bb0120","first-page":"15s","article-title":"An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin\u2019s lymphoma (FL)","volume":"27","author":"Kingsley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr555_bb0125","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/JTO.0b013e31820a0ea6","article-title":"Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer","volume":"6","author":"Ready","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdr555_bb0130","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1097\/JTO.0b013e3181e8f4dc","article-title":"Phase I\/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer","volume":"5","author":"Heist","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdr555_bb0135","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdn784","article-title":"Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer","volume":"20","author":"Sternberg","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr555_bb0140","first-page":"18s","article-title":"A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401","volume":"28","author":"Kelly","year":"2010","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1093\/annonc\/mdr555_bb0145","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.26.8771","article-title":"Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Chi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr555_bb0150","article-title":"SYNERGY: a randomized phase III study comparing first-line docetaxel\/prednisone to docetaxel\/prednisone plus custirsen in metastatic castrate-resistant prostate cancer","volume":"29","author":"Chi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdr555_bb0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1093\/annonc\/mdr555_bb0160","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/jcb.22633","article-title":"AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model","volume":"110","author":"McGregor","year":"2010","journal-title":"J Cell Biochem"},{"issue":"5","key":"10.1093\/annonc\/mdr555_bb0165","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/cdd.2009.171","article-title":"BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists","volume":"17","author":"Goldsmith","year":"2010","journal-title":"Cell Death Differ"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419380093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419380093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/7\/1803\/16703355\/mdr555.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:11:00Z","timestamp":1624684260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419380093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0923753419380093"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr555","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}